Deprenyl treatment restores serum insulin-like growth factor-I (IGF-I) levels in aged rats to young rat level

De la Cruz CP, Revilla E, Rodriguez-Gomez JA,
Vizuete ML, Cano J, Machado A

Departamento de Bioquimica,
Bromatologia y Toxicologia,
Facultad de Farmacia,
Universidad de Sevilla, Spain.
Eur J Pharmacol 1997 May 30; 327(2-3):215-20


We studied the effects of treatment with (-)-deprenyl, a monoamine oxidase B inhibitor, on plasma levels of insulin-like growth factor-I (IGF-I) (as indicator of growth hormone (GH) secretion), levels of monoamines and their metabolites, and the activity and content of tyrosine hydroxylase - the rate-limiting enzyme in the biosynthesis of catecholamines - in the hypothalamus and hypophysis of old male rats.  Male Wistar rats (22 months old) were treated with 2 mg deprenyl/kg body weight s.c. three times a week for 2 months.  At the end of the treatment period, blood was collected for measurement of plasma IGF-I levels by radioimmunoassay (RIA).  The concentrations of dopamine, serotonin (5-HT) and their main metabolites were determined by high performance liquid chromatography (HPLC) with electrochemical detection, and the tyrosine hydroxylase content in hypothalamus and hypophysis was determined by enzyme-linked immunoabsorbent assay (ELISA). (-)-Deprenyl treatment produced a pronounced increase in dopamine and 5-HT in both the hypothalamus and hypophysis (P < 0.01).  The main dopaminergic metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC), decreased in hypothalamus but not in hypophysis, and treatment had no effect on the concentration of 5-hydroxyindole-3-acetic acid (5-HIAA).  The tyrosine hydroxylase activity and tyrosine hydroxylase content increased in hypothalamus and hypophysis (P < 0.05). In the hypophysis the increase in tyrosine hydroxylase activity was consistent with the increase in tyrosine hydroxylase amount. Moreover, (-)-deprenyl treatment restored the IGF-I plasma levels in old rats to a concentration similar to those found in young animals. Postulated anti-aging effects of (-)-deprenyl could hence be due to restoration of hypothalamic hormones such as GH.
Alzheimer's research

1.    Deprenyl  for Alzheimer's disease  
2.    Deprenyl  MAO-B inhibitors in the treatment of Alzheimer's disease
3.    Deprenyl  stimulates biosynthesis of cytokines interleukin-1 & 6
4.    Deprenyl 
and age-related decline of the striatal dopaminergic system
.    Deprenyl
  in the treatment of Alzheimer's disease
6.    Deprenyl  improves memory in amnesic Alzheimer's patients
7.    Deprenyl  treatment of behavioral symptoms of Alzheimer's disease